The global asthma treatment market size is expected to reach USD 26.10 billion by 2030 according to a new study by Polaris Market Research. The report “Asthma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Anti-Inflammatory, Bronchodilators, Combination Therapies, Others); By Device Type; By Route of Administration; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
According to the WHO report, in 2022, 262 million people were affected by asthma in 2019, and 455000 deaths were recorded worldwide. This is due to the rising urbanization, imbalanced lifestyle, occasions in early life affecting the lungs and building the risk of asthma-like low birth weight, rashness, openness to tobacco smoke and different wellsprings of air contamination, as well as viral respiratory diseases, exposure to a scope of ecological allergens and aggravations. The other factors include indoor and outside air contamination, house dust bugs, molds, and word-related openness to synthetic substances, vapor, or residue.
As per the study conducted by the American college of allergy, breathing problem & immunology, around 8.3% of Americans suffer from breathing problem, out of 26.5 million, 20.4 million are adults, and 6.1 million are children. According to the Centers for Disease Control and Prevention (CDC), in 2019, a total of 1,835,901 total emergency hospital cure were recorded, including children (age <18 years) to adults, age 18+ years, and 309,330 patients, including children and adults were admitted in hospital for treatment.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/global-asthma-treatment-market/request-for-sample
Asthma Treatment Market Report Highlights
- North America market is expected to register one of the highest cases of asthma cure due to the increasing number of cases yearly.
- The intravenous segment is expected to register the fastest growth during the forecast period. FDA has approved Tezspire, which would act as an add-on cure for severe cases that regular medications can’t control. Tezspire is extraordinary because it isn’t restricted to a particular kind of extreme breathing problems. It focuses on a type of particle engaged with aviation route irritation. FDA approves the drug after its two successful trials.
- Market participants such as Amgen, Merck & Co., Inc., Abbott, Biogen, Boehringer Ingelheim International GmbH, Sanofi, Novartis AG, AstraZeneca plc., Sunovion Pharmaceuticals, Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Mylan N.V., Roche AG, and Teva Pharmaceutical Industries are some of the key players operating in the market.
- In July 2020, AstraZeneca’s outcomes from the positive Phase III ETHOS preliminary were distributed in the New England Journal of Medicine. The review showed that the triple-mix treatment PT010 (budesonide/glycopyrronium/formoterol fumarate) reduced the rate of moderate or extreme intensifications compared with two double blend treatments in patients with moderate to severe COPD.
Polaris Market Research has segmented the asthma treatment market report based on device type, drug class, route of administration, and region:
Asthma Treatment, Drug Class Outlook (Revenue – USD Billion, 2018 – 2030)
- Combination Therapy
Asthma Treatment, Device Type Outlook (Revenue – USD Billion, 2018 – 2030)
- Dry Powder Inhalers
- Metered Dose Inhalers
- Soft Mist Inhalers
Asthma Treatment, Route of Application Outlook (Revenue – USD Billion, 2018 – 2030)
Asthma Treatment Regional Outlook (Revenue – USD Billion, 2018 – 2030)
- North America
- Asia Pacific
- South Africa
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa